首页 | 本学科首页   官方微博 | 高级检索  
检索        

促性腺激素释放激素激动剂联合左炔诺孕酮宫内缓释系统治疗子宫腺肌病的效果分析
引用本文:颜慧,彭丽秀,.促性腺激素释放激素激动剂联合左炔诺孕酮宫内缓释系统治疗子宫腺肌病的效果分析[J].中国医学工程,2020(5):33-35.
作者姓名:颜慧  彭丽秀  
作者单位:郴州市第一人民医院妇科;
摘    要:目的探讨促性腺激素释放激素激动剂联合左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床效果。方法选取2016年1月至2018年10月该院收治的子宫腺肌病(AM)患者72例。按随机双盲法分为对照组(n=36)采用左炔诺孕酮宫内缓释系统(LNG-IUS)治疗;观察组(n=36)采用促性腺激素释放激素激动剂(GnRH-a)联合LNG-IUS治疗;比较两组患者治疗前后痛经程度、子宫体积及不良反应。结果观察组治疗3个月、6个月后痛经程度分别为(2.65±0.72)分、(2.14±0.56)分,均低于对照组的(3.34±0.81)分、(3.18±0.58)分,治疗3个月、6个月后子宫体积小于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论促性腺激素释放激素激动剂联合左炔诺孕酮宫内缓释系统治疗子宫腺肌病获得理想效果,能缓解痛经症状,抑制子宫体积增大,具有一定推广意义。

关 键 词:促性腺激素释放激素激动剂  左炔诺孕酮宫内缓释系统  子宫腺肌病

Gonadotropin-releasing hormone agonist combined with levonorgestrel intrauterine sustained-release system in treatment of adenomyosis
YAN Hui,PENG Lixiu.Gonadotropin-releasing hormone agonist combined with levonorgestrel intrauterine sustained-release system in treatment of adenomyosis[J].China Medical Engineering,2020(5):33-35.
Authors:YAN Hui  PENG Lixiu
Institution:(Department of Gynecology,Chenzhou First People's Hospital,Chenzhou,Hunan 423000,China)
Abstract:【Objective】To investigate the clinical effect of gonadotropin-releasing hormone agonist(GnRH-a)combined with levonorgestrel intrauterine sustained-release system(LNG-IUS)on adenomyosis.【Methods】Seventy-two patients with adenomyosis(AM)admitted to our hospital from January 2016 to October 2018 were selected.According to randomized doubleblind method they were divided into two groups,the control group(n=36)was treated with levonorgestrel LNG-IUS,and the observation group(n=36)was treated with GnRH-a combined with LNG-IUS treatment.The degree of dysmenorrhea,uterine volume and adverse reactions were compared between the two groups before and after treatment.【Results】The degree of dysmenorrhea in the observation group after treatment for 3 months and 6 months were 2.65±0.72 points and 2.14±0.56 points,which were lower than those in the control group(3.34±0.81 points and 3.18±0.58 points).Three or 6 months after treatment,the uterine volume in the observation group was smaller than that in the control group(P<0.05).The difference in the incidence of adverse reactions between the two groups was not statistically significant(P>0.05).【Conclusion】Gonadotropin-releasing hormone agonist combined with levonorgestrel intrauterine sustained-release system in the treatment of adenomyosis has an ideal effect to relieve the symptoms of dysmenorrhea and inhibit the increase of uterine volume,which has certain promotion significance.
Keywords:gonadotropin-releasing hormone agonist  levonorgestrel intrauterine sustained-release system  adenomyosis
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《中国医学工程》浏览原始摘要信息
点击此处可从《中国医学工程》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号